Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]
Entrada Therapeutics announced encouraging new data on their exon 44 skipping program following their presentation at TIDES USA 2022. CureDuchenne provided funding to Entrada last year as part of their Series […]
Premier Wine Series Brought Together Most Acclaimed Napa Valley Vintners Under One Roof in Philadelphia to Benefit Global Nonprofit CureDuchenne NEWPORT BEACH Calif., April 27, 2022 – CureDuchenne, a leading […]
Initiation of AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne will be delayed. This January, we shared the news that REGENXBIO received clearance from the U.S. FDA and would […]
Pfizer’s Letter to the Duchenne Community We are pleased to share the good news that several regulatory authorities have approved the re-start of our Phase 3 ambulatory trial (CIFFREO) for […]
Today, Solid Biosciences announced a change to its corporate strategy to better align resources with goals to bring SGT-001 and SGT-003 to patients. Key Takeaways: Enrollment in IGNITE DMD, its […]
We are pleased to share that Edgewise Therapeutics is sponsoring a natural history study in Becker muscular dystrophy, to better understand the course of disease and define endpoints to be […]
Registration Now Open for Three-Day National Conference in Orlando, Welcoming Attendees From Across the Globe Newport Beach, Calif. (March 25, 2022) – CureDuchenne, a leading global nonprofit focused on finding […]
The Event Brought the Austin Community Together for a Night of Fun with a Purpose Featuring Gourmet Food, Cocktails, Casino Games and More NEWPORT BEACH, Calif., April 6, 2022 – […]
